— Know what they know.
Not Investment Advice

NNNN NASDAQ

Anbio Biotechnology Class A Ordinary Shares
1W: +3.5% 1M: -36.6% 3M: -66.7% YTD: -86.9% 1Y: -83.2%
$3.71
+0.01 (+0.27%)
 
Weekly Expected Move ±15.1%
$3 $3 $4 $4 $5
NASDAQ · Healthcare · Medical - Instruments & Supplies · Tech Score Sell · Power 32 · $162.8M mcap · 40M float · 0.310% daily turnover · Short 47% of daily vol
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Cash Flow Trends

Operating Cash Flow
$2M +131.6% ▲
3Y CAGR: -20.8%
Capital Expenditures
$0 +0.0% ▲
Free Cash Flow
$2M +131.6% ▲
3Y CAGR: -20.8%
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$2M -19.8% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024
— Operating Activities —
Net Income$3M$10M$2M$2M
Depreciation & Amort.$0$6K$12K$0
Stock-Based Comp.$0$0$0$0
Change in Working Capital$2M-$6M-$1M$45K
Other Non-Cash Items$0-$41K-$163K-$337K
Operating Cash Flow$4M$4M$898K$2M
— Investing Activities —
Capital Expenditures$0$0$0$0
Acquisitions (Net)$0$0$0$0
Investment Purchases$0-$16M-$19M-$35M
Investment Sales$0$15M$20M$36M
Other Investing$0$0$0$0
Investing Cash Flow$0-$2M$2M$337K
— Financing Activities —
Net Debt Issuance$0$0$0$0
Stock Repurchased$0$0$0$0
Dividends Paid$0$0$0$0
Other Financing$0$0-$43K-$345K
Financing Cash Flow$0$0-$43K-$345K
Net Change in Cash$4M$3M$3M$2M
Cash End of Period$4M$7M$10M$12M
Free Cash Flow$4M$4M$898K$2M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms